Cargando…

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Packnett, Elizabeth R., Winer, Isabelle H., Larkin, Heather, Oladapo, Abiola, Gonzales, Tara, Wojdyla, Matthew, Goldstein, Mitchell, Smith, Vincent C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Immunotherapeutics – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746385/ https://www.ncbi.nlm.nih.gov/pubmed/36412253 http://dx.doi.org/10.1080/21645515.2022.2140533

Ejemplares similares

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Immunotherapy of glioblastoma: Recent advances and future prospects
por: Yuan, Boyang, et al.
Publicado: (2022)

The progress of peptide vaccine clinical trials in gynecologic oncology
por: Tang, Mi, et al.
Publicado: (2022)

Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity
por: Scendoni, Roberto, et al.
Publicado: (2022)

Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022)

Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases
por: Hua, Chunting, et al.
Publicado: (2022)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
por: Nagata, Yusuke, et al.
Publicado: (2022)

The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies
por: Ling, Qiaoyun, et al.
Publicado: (2022)

Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
por: Zhu, Yahui, et al.
Publicado: (2022)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

WGA is a probe for migrasomes
por: Chen, Lilian, et al.
Publicado: (2019)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation
por: Goldstein, Mitchell, et al.
Publicado: (2021)

Introduction
por: Zhao, Peter, et al.
Publicado: (2011)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma
por: Mansh, Matthew
Publicado: (2011)

Regulating Caspase-1 During Infection: Roles of NLRs, AIM2, and ASC
por: Case, Christopher L.
Publicado: (2011)

Cancer Immunotherapy Takes a Multi-Faceted Approach to Kick the Immune System into Gear
por: Dimberu, Peniel M., et al.
Publicado: (2011)

Learning to Live Together: Harnessing Regulatory T cells to Induce Organ Transplant Tolerance
por: Chang, Andrew Y., et al.
Publicado: (2011)

Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
por: Flies, Dallas B., et al.
Publicado: (2011)

Nanoparticle Delivery of Anti-Tuberculosis Chemotherapy as a Potential Mediator Against Drug-Resistant Tuberculosis
por: Smith, Jonathan Paul
Publicado: (2011)

Vaccination: The Present and the Future
por: Sadanand, Saheli
Publicado: (2011)

Development and evaluation of a tetravalent botulinum vaccine
por: Shi, Dan-Yang, et al.
Publicado: (2022)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) mediate protection against influenza a viral infection
por: Gleason, Joseph, et al.
Publicado: (2022)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

MicroRNA-873-5p suppresses cell malignant behaviors of thyroid cancer via targeting CXCL5 and regulating P53 pathway
por: Chang, Wang, et al.
Publicado: (2022)

Update about Oralair® as a treatment for grass pollen allergic rhinitis
por: Klimek, L., et al.
Publicado: (2022)

Relationship between T-cell-dependent and T-cell-independent vaccines after neurotrauma; is the B-cell response preserved?
por: Ljunghill Hedberg, Anna, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy
por: Berger, Peer Andre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upcrlv90th26bb85m37p3ba195